A detailed history of Pro Share Advisors LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 15,681 shares of PTGX stock, worth $686,827. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,681
Previous 11,270 39.14%
Holding current value
$686,827
Previous $390,000 80.51%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $148,738 - $208,772
4,411 Added 39.14%
15,681 $704,000
Q2 2024

Aug 13, 2024

SELL
$24.66 - $34.8 $75,829 - $107,009
-3,075 Reduced 21.44%
11,270 $390,000
Q1 2024

May 08, 2024

BUY
$21.79 - $32.15 $26,278 - $38,772
1,206 Added 9.18%
14,345 $415,000
Q4 2023

Feb 14, 2024

BUY
$14.05 - $23.44 $27,495 - $45,872
1,957 Added 17.5%
13,139 $301,000
Q3 2023

Nov 13, 2023

BUY
$16.68 - $23.66 $7,122 - $10,102
427 Added 3.97%
11,182 $186,000
Q2 2023

Aug 10, 2023

BUY
$18.02 - $29.36 $33,679 - $54,873
1,869 Added 21.03%
10,755 $297,000
Q1 2023

May 11, 2023

BUY
$10.78 - $25.38 $95,791 - $225,526
8,886 New
8,886 $204,000
Q2 2022

Aug 01, 2022

SELL
$7.06 - $25.52 $94,596 - $341,942
-13,399 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$23.34 - $36.08 $72,120 - $111,487
-3,090 Reduced 18.74%
13,399 $317,000
Q4 2021

Feb 08, 2022

BUY
$17.63 - $37.1 $10,525 - $22,148
597 Added 3.76%
16,489 $564,000
Q3 2021

Nov 12, 2021

SELL
$12.95 - $49.69 $35,340 - $135,604
-2,729 Reduced 14.66%
15,892 $282,000
Q2 2021

Aug 13, 2021

BUY
$25.57 - $44.88 $83,204 - $146,039
3,254 Added 21.18%
18,621 $836,000
Q1 2021

May 14, 2021

BUY
$19.02 - $31.15 $47,397 - $77,625
2,492 Added 19.36%
15,367 $398,000
Q4 2020

Feb 09, 2021

BUY
$18.49 - $25.13 $238,058 - $323,548
12,875 New
12,875 $260,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.15B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.